Nacubactam (also known as RG6080 and OP0595) is a novel dual-action β-lactamase inhibitor in development in combination with meropenem (MEM) for treatment of infections caused by β-lactamase-producing Enterobacteriaceae, including carbapenem-resistant pathogens. Nacubactam is a member of the growing class of bridged diazabicyclooctane (DBO) β- lactamase inhibitors. Nacubactam inhibits Escherichia coli penicillin binding protein 2 (PBP2). Moreover, nacubactam was reported to act synergistically as a β-lactam enhancer, like mecillinam and other DBOs (WCK 5153 and zidebactam), when combined with β-lactams. This enhancer effect is the result of these combinations possessing the ability to target multiple PBPs.
Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API). This monograph also contains the acceptable daily exposure (ADE) value.
OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), as well as PIC/S and ANVISA requirements, and to obtain the following information:
To order an OEL/ADE monograph for Nacubactam, just click the ADD TO CART button.
If you're wondering about HBEL, we have something for you.
Not the compound you were looking for? You can search the OEL Fastrac catalog to find more available compounds.
Affygility Solutions’ OEL Fastrac service is an user-friendly system that enables us to make confident decisions and focus on moving the compound safely through our facility. We can quickly access the database to determine if a new drug is within the OEL Fastrac library, and if so, immediately download a detailed OEL banding report. The OEL Fastrac system has been a helpful tool in our overall EH&S program.